RARE – Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc.RARE
$28.44Name : Ultragenyx Pharmaceutical Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $2,688,774,656.00
EPSttm : -5.83
Ultragenyx Pharmaceutical Inc.
$28.44
4.10%$1.12Float Short %
9.96
Margin Of Safety %
Put/Call OI Ratio
0.6
EPS Next Q Diff
0.26
EPS Last/This Y
0.97
EPS This/Next Y
1.75
Price
28.44
Target Price
84.6
Analyst Recom
1.2
Performance Q
-27.02
Relative Volume
1.27
Beta
0.24
Ticker: RARE
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-07-04 | RARE | 40 | 0.57 | 1.41 | 70133 |
| 2025-07-07 | RARE | 39.63 | 0.57 | 1.34 | 69980 |
| 2025-07-08 | RARE | 39.42 | 0.60 | 0.84 | 74137 |
| 2025-07-09 | RARE | 41.43 | 0.61 | 0.51 | 74984 |
| 2025-07-10 | RARE | 31.05 | 0.59 | 1.30 | 83723 |
| 2025-07-11 | RARE | 29.51 | 0.51 | 0.64 | 87299 |
| 2025-07-14 | RARE | 29.35 | 0.49 | 1.50 | 90445 |
| 2025-07-15 | RARE | 27.22 | 0.51 | 1.40 | 94268 |
| 2025-07-16 | RARE | 27.23 | 0.52 | 4.07 | 96719 |
| 2025-07-17 | RARE | 27.41 | 0.54 | 3.18 | 99082 |
| 2025-07-18 | RARE | 26.32 | 0.52 | 1.12 | 97562 |
| 2025-07-21 | RARE | 26.4 | 0.68 | 0.76 | 68880 |
| 2025-07-22 | RARE | 26.43 | 0.68 | 0.12 | 69361 |
| 2025-07-23 | RARE | 27.92 | 0.67 | 0.11 | 70029 |
| 2025-07-24 | RARE | 27.29 | 0.63 | 0.05 | 72182 |
| 2025-07-25 | RARE | 27.34 | 0.63 | 0.11 | 72397 |
| 2025-07-28 | RARE | 27.6 | 0.61 | 0.28 | 73947 |
| 2025-07-29 | RARE | 27.68 | 0.60 | 0.05 | 74519 |
| 2025-07-30 | RARE | 27.14 | 0.60 | 0.64 | 74687 |
| 2025-07-31 | RARE | 27.4 | 0.60 | 0.08 | 75051 |
| 2025-08-01 | RARE | 28.36 | 0.60 | 0.32 | 75754 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-07-04 | RARE | 39.91 | 12.7 | - | -5.32 |
| 2025-07-07 | RARE | 39.63 | 12.7 | - | -5.32 |
| 2025-07-08 | RARE | 39.42 | 12.7 | - | -5.32 |
| 2025-07-09 | RARE | 41.44 | 12.7 | - | -5.32 |
| 2025-07-10 | RARE | 31.03 | 12.7 | - | -5.32 |
| 2025-07-11 | RARE | 29.51 | 12.7 | - | -5.32 |
| 2025-07-14 | RARE | 29.23 | 12.7 | - | -5.32 |
| 2025-07-15 | RARE | 27.20 | 12.7 | - | -5.32 |
| 2025-07-16 | RARE | 27.32 | 12.7 | - | -5.32 |
| 2025-07-17 | RARE | 27.41 | 12.7 | - | -5.32 |
| 2025-07-18 | RARE | 26.33 | 12.7 | - | -5.32 |
| 2025-07-21 | RARE | 26.39 | 12.7 | - | -5.32 |
| 2025-07-22 | RARE | 26.45 | 12.7 | - | -5.32 |
| 2025-07-23 | RARE | 28.01 | 12.7 | - | -5.32 |
| 2025-07-24 | RARE | 27.30 | 12.7 | - | -5.32 |
| 2025-07-25 | RARE | 27.34 | 12.8 | - | -5.33 |
| 2025-07-28 | RARE | 27.62 | 12.8 | - | -5.33 |
| 2025-07-29 | RARE | 27.66 | 12.8 | - | -5.33 |
| 2025-07-30 | RARE | 27.14 | 12.8 | 0.9 | -5.33 |
| 2025-07-31 | RARE | 27.32 | 13.1 | -13.8 | -5.32 |
| 2025-08-01 | RARE | 28.44 | 13.1 | -34.4 | -5.32 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-07-04 | RARE | -2.60 | 2.57 | 6.88 |
| 2025-07-07 | RARE | -2.60 | 2.58 | 6.88 |
| 2025-07-08 | RARE | -2.60 | 2.58 | 6.88 |
| 2025-07-09 | RARE | -2.60 | 2.58 | 6.88 |
| 2025-07-10 | RARE | -2.60 | 2.58 | 6.88 |
| 2025-07-11 | RARE | -2.60 | 2.58 | 7.72 |
| 2025-07-14 | RARE | -2.60 | 2.59 | 7.72 |
| 2025-07-15 | RARE | -2.60 | 2.59 | 7.72 |
| 2025-07-16 | RARE | -2.60 | 2.59 | 7.72 |
| 2025-07-17 | RARE | -2.60 | 2.59 | 7.72 |
| 2025-07-18 | RARE | -2.60 | 2.59 | 7.72 |
| 2025-07-21 | RARE | -2.60 | 3.72 | 7.72 |
| 2025-07-22 | RARE | -2.60 | 3.72 | 7.72 |
| 2025-07-23 | RARE | -2.60 | 3.72 | 7.72 |
| 2025-07-24 | RARE | -2.60 | 3.72 | 7.72 |
| 2025-07-25 | RARE | -2.60 | 3.72 | 9.96 |
| 2025-07-28 | RARE | -2.60 | 3.50 | 9.96 |
| 2025-07-29 | RARE | -2.60 | 3.50 | 9.96 |
| 2025-07-30 | RARE | -2.60 | 3.50 | 9.96 |
| 2025-07-31 | RARE | -2.60 | 3.50 | 9.96 |
| 2025-08-01 | RARE | -2.60 | 3.50 | 9.96 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-1.57
Avg. EPS Est. Current Quarter
-1.33
Avg. EPS Est. Next Quarter
-1.31
Insider Transactions
-2.6
Institutional Transactions
3.5
Beta
0.24
Average Sales Estimate Current Quarter
161
Average Sales Estimate Next Quarter
164
Fair Value
Quality Score
38
Growth Score
52
Sentiment Score
79
Actual DrawDown %
84.2
Max Drawdown 5-Year %
-85.2
Target Price
84.6
P/E
Forward P/E
PEG
P/S
4.55
P/B
18.48
P/Free Cash Flow
EPS
-5.88
Average EPS Est. Cur. Y
-5.32
EPS Next Y. (Est.)
-3.56
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-93.04
Relative Volume
1.27
Return on Equity vs Sector %
-404.7
Return on Equity vs Industry %
-386.1
EPS 1 7Days Diff
EPS 1 30Days Diff
0.01
EBIT Estimation
-34.4
Ultragenyx Pharmaceutical Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 1294
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Europe, the Middle East, Africa, and the Asia-Pacific. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidates that are in Phase 3 clinical trials include UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; and GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome. It also develops UX701 that is in Phase 2 clinical trial for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; GeneTx; Mereo; University of Pennsylvania; Solid Biosciences Inc.; Regeneron; Abeona; and Arcturus Therapeutics Holdings Inc. The company was incorporated in 2010 and is headquartered in Novato, California.
stock quote shares RARE – Ultragenyx Pharmaceutical Inc. Stock Price stock today
news today RARE – Ultragenyx Pharmaceutical Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch RARE – Ultragenyx Pharmaceutical Inc. yahoo finance google finance
stock history RARE – Ultragenyx Pharmaceutical Inc. invest stock market
stock prices RARE premarket after hours
ticker RARE fair value insiders trading